Kestra Medical Technologies, Ltd. officer Vaseem Mahboob filed a Form 144 notice on October 27, 2026, disclosing a proposed sale of 34,809 shares of common stock acquired through a broker-assisted cashless exercise of employee stock options on the same date.

Key Highlights

  • Proposed sale size: 34,809 shares of Kestra Medical Technologies common stock, with an aggregate market value of $1,045,784.87.
  • Acquisition method: Shares were acquired on October 27, 2026, via a broker-assisted cashless exercise of employee stock options granted by Kestra Medical Technologies, Ltd.
  • Broker: Merrill Lynch, 225 Liberty Street, Floor 37, New York, NY 10281, is named as the executing broker.
  • Total shares outstanding: 59,561,795 shares of common stock were outstanding at the time of the notice.
  • Prior three-month sales: Mahboob sold a combined 51,470 shares in four transactions between July 30, 2026, and August 7, 2026, generating gross proceeds totaling $1,271,235.20.
  • Rule 10b5-1 plan: The notice indicates a plan adoption date of November 5, 2025.
  • Exchange: The securities are listed on NASDAQ (NASDAQ:KMTS is not stated in the filing; the filing names only "NASDAQ" as the exchange and does not provide a ticker symbol).

Mahboob's Proposed Sale and Recent Transaction History at Kestra Medical

According to the Form 144 filing dated October 27, 2026, Vaseem Mahboob, identified as an officer of Kestra Medical Technologies, Ltd. (SEC File Number 001-42549), intends to sell 34,809 shares of the company's common stock. The filing discloses that the shares were acquired on October 27, 2026, through a broker-assisted cashless exercise of employee stock options, with Kestra Medical Technologies, Ltd. listed as the entity from whom the shares were acquired. The approximate date of the proposed sale is listed as October 27, 2026.

The filing also discloses sales of Kestra Medical common stock by Mahboob during the three months preceding the notice. Those transactions, as reported, consisted of four separate sales: 3,980 shares on July 30, 2026, generating gross proceeds of $90,560.62; 8,817 shares on July 31, 2026, generating $199,344.62; 5,391 shares on August 3, 2026, generating $128,312.27; 6,995 shares on August 4, 2026, generating $172,634.70; and 26,287 shares on August 7, 2026, generating $680,383.99. The filing lists Mahboob's address as 3933 Lake Washington Blvd NE, Suite 200, Kirkland, WA 98033, which is the same address as the issuer.

The notice states that a written trading plan or instruction was adopted on November 5, 2025, indicating the proposed sale may be conducted pursuant to Rule 10b5-1 under the Exchange Act. By signing the form, Mahboob represents that he "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed," as stated in the filing's standard attestation language.

What Was Disclosed

A Form 144 notice of proposed sale was filed on October 27, 2026, by Kestra Medical Technologies officer Vaseem Mahboob, covering 34,809 shares acquired via cashless stock option exercise, with an aggregate market value of $1,045,784.87, to be sold through Merrill Lynch on NASDAQ.